Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rania El Botty

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Cancer Research Communications|February 11, 2025
Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical StudyWilliam C Reinhold, Elisabetta Marangoni, Fathi Elloumi, et al.
Cancer Research|October 6, 2023
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast CancersArany Soosainathan, Marjan Iravani, Rania El-Botty, et al.
Journal of Hematology & Oncology|September 9, 2021
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breastIvan Bièche, Florence Coussy, Rania El-Botty, et al.
Breast Cancer Research : BCR|May 22, 2021
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrantJulien Jacquemetton, Loay Kassem, Coralie Poulard, et al.
Oncotarget|May 19, 2018
Selumetinib-based therapy in uveal melanoma patient-derived xenograftsDidier Decaudin, Rania El Botty, Béré Diallo, et al.
Cancers|August 29, 2024
Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer PatientsDidier Decaudin, Fariba Némati, Julien Masliah Planchon, et al.
Biomaterials|January 9, 2021
In vitro bone metastasis dwelling in a 3D bioengineered nicheWeijing Han, Rania El Botty, Elodie Montaudon, et al.
Molecular Oncology|February 28, 2023
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancersRania El-Botty, Sophie Vacher, Juliette Mainguené, et al.
Cancers|March 25, 2022
Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in <i>PBRM1</i>-Mutated Human Chordoma XenograftThibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, et al.
Cancer Research|November 7, 2025
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast CancerFrancesca Bonechi, Marina Bacci, Nicla Lorito, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Cancer Research Communications|February 11, 2025
Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical StudyWilliam C Reinhold, Elisabetta Marangoni, Fathi Elloumi, et al.
Cancer Research|October 6, 2023
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast CancersArany Soosainathan, Marjan Iravani, Rania El-Botty, et al.
Journal of Hematology & Oncology|September 9, 2021
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breastIvan Bièche, Florence Coussy, Rania El-Botty, et al.
Breast Cancer Research : BCR|May 22, 2021
Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrantJulien Jacquemetton, Loay Kassem, Coralie Poulard, et al.
Oncotarget|May 19, 2018
Selumetinib-based therapy in uveal melanoma patient-derived xenograftsDidier Decaudin, Rania El Botty, Béré Diallo, et al.
Cancers|August 29, 2024
Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer PatientsDidier Decaudin, Fariba Némati, Julien Masliah Planchon, et al.
Biomaterials|January 9, 2021
In vitro bone metastasis dwelling in a 3D bioengineered nicheWeijing Han, Rania El Botty, Elodie Montaudon, et al.
Molecular Oncology|February 28, 2023
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancersRania El-Botty, Sophie Vacher, Juliette Mainguené, et al.
Cancers|March 25, 2022
Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in <i>PBRM1</i>-Mutated Human Chordoma XenograftThibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, et al.
Cancer Research|November 7, 2025
ESR1 Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast CancerFrancesca Bonechi, Marina Bacci, Nicla Lorito, et al.
Pageof 4